John M Stone1, Andrew Savage2, Michelle Hudspeth3, Katherine Twombley4, Nagraj Kasi1, Jose Antonio Quiros5, Ricardo A Arbizu1, Scott Curry6. 1. Department of Pediatric Gastroenterology Hepatology and Nutrition, Medical University of South Carolina, Charleston, South Carolina, USA. 2. Department of Pediatric Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA. 3. Department of Pediatric Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, USA. 4. Department of Pediatric Nephrology, Medical University of South Carolina, Charleston, South Carolina, USA. 5. Department of Pediatric Gastroenterology Hepatology and Nutrition, Mount Sinai Kravis Children's Hospital, New York, New York, USA. 6. Department of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA.
Abstract
BACKGROUND: Diarrhea is a common problem in the pediatric post-solid organ transplant and post-hematopoietic stem cell transplant populations. Infectious etiology incidences are poorly defined, and the possibility of multi-organism positivity is often uninvestigated. The aim of this study is to utilize stool multiplex GIP assays to compare the PTP and NTP regarding the incidence and profiles of single-organism and multi-organism infectious diarrhea. METHODS: A single-center retrospective review was conducted, investigating stool multiplex GIP panel results over a more than 3-year period, for pediatric patients. Assays test for 23 viral, bacterial, and protozoal organisms. RESULTS: Positive assays in the PTP and NTP were 70/101 (69.3%) and 962/1716 (56.1%), respectively (P = .009). Thirty-two percent (32/101) of assays within the PTP were multi-organism positive, significantly more than 14.8% (254/1716) in the NTP (P < .00001). There was no significant difference in the incidence of single-organism positives, 37.6% (38/101) in PTP and 41.3% (708/1716) in the NTP. The PTP demonstrated a statistically significantly higher incidence of the following organisms within multi-agent positive GIPs (P < .05 for each): Clostridioides difficile, Cryptosporidium, EPEC, norovirus, and sapovirus. CONCLUSIONS: The pediatric PTP demonstrates higher incidence of positive GIPs, higher rate of multi-organism positivity, and unique infectious organism incidence profiles. These data can provide a framework for understanding organism-specific pathogenicity factors, assessing the clinical impact of enteric co-infection, and understanding the utility of this testing modality in this unique population.
BACKGROUND:Diarrhea is a common problem in the pediatric post-solid organ transplant and post-hematopoietic stem cell transplant populations. Infectious etiology incidences are poorly defined, and the possibility of multi-organism positivity is often uninvestigated. The aim of this study is to utilize stool multiplex GIP assays to compare the PTP and NTP regarding the incidence and profiles of single-organism and multi-organism infectious diarrhea. METHODS: A single-center retrospective review was conducted, investigating stool multiplex GIP panel results over a more than 3-year period, for pediatric patients. Assays test for 23 viral, bacterial, and protozoal organisms. RESULTS: Positive assays in the PTP and NTP were 70/101 (69.3%) and 962/1716 (56.1%), respectively (P = .009). Thirty-two percent (32/101) of assays within the PTP were multi-organism positive, significantly more than 14.8% (254/1716) in the NTP (P < .00001). There was no significant difference in the incidence of single-organism positives, 37.6% (38/101) in PTP and 41.3% (708/1716) in the NTP. The PTP demonstrated a statistically significantly higher incidence of the following organisms within multi-agent positive GIPs (P < .05 for each): Clostridioides difficile, Cryptosporidium, EPEC, norovirus, and sapovirus. CONCLUSIONS: The pediatric PTP demonstrates higher incidence of positive GIPs, higher rate of multi-organism positivity, and unique infectious organism incidence profiles. These data can provide a framework for understanding organism-specific pathogenicity factors, assessing the clinical impact of enteric co-infection, and understanding the utility of this testing modality in this unique population.
Authors: B Maes; K Hadaya; B de Moor; P Cambier; P Peeters; J de Meester; J Donck; J Sennesael; J-P Squifflet Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: Jason Kim; Sarah A Smathers; Priya Prasad; Kateri H Leckerman; Susan Coffin; Theoklis Zaoutis Journal: Pediatrics Date: 2008-12 Impact factor: 7.124
Authors: J I Herrero; S Benlloch; A Bernardos; I Bilbao; L Castells; J F Castroagudin; L González; I Irastorza; M Navasa; A Otero; J A Pons; A Rimola; F Suárez; T Casanovas; E Otero; M Rodríguez; T Serrano; S Otero; I López; M Miras; M Prieto Journal: Transplant Proc Date: 2007-09 Impact factor: 1.066
Authors: Maribeth R Nicholson; Isaac P Thomsen; James C Slaughter; C Buddy Creech; Kathryn M Edwards Journal: J Pediatr Gastroenterol Nutr Date: 2015-01 Impact factor: 2.839